Concepts (181)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vasculitis | 2 | 2018 | 49 | 0.800 |
Why?
|
| Paraneoplastic Syndromes, Nervous System | 1 | 2020 | 2 | 0.630 |
Why?
|
| ELAV Proteins | 1 | 2020 | 2 | 0.630 |
Why?
|
| Leprosy | 2 | 2014 | 8 | 0.620 |
Why?
|
| Antibodies, Antinuclear | 1 | 2020 | 41 | 0.610 |
Why?
|
| Mononeuropathies | 2 | 2018 | 5 | 0.610 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 64 | 0.600 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 50 | 0.590 |
Why?
|
| Autoantigens | 1 | 2020 | 140 | 0.580 |
Why?
|
| Minocycline | 1 | 2018 | 28 | 0.540 |
Why?
|
| Polyneuropathies | 2 | 2009 | 13 | 0.520 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2016 | 2324 | 0.490 |
Why?
|
| Lipodystrophy | 1 | 2016 | 11 | 0.480 |
Why?
|
| Subcutaneous Fat | 1 | 2016 | 50 | 0.460 |
Why?
|
| Neuromuscular Diseases | 3 | 2018 | 24 | 0.430 |
Why?
|
| Neuroma | 1 | 2014 | 1 | 0.410 |
Why?
|
| Sural Nerve | 1 | 2014 | 2 | 0.410 |
Why?
|
| Electrodiagnosis | 3 | 2020 | 20 | 0.410 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2011 | 58 | 0.400 |
Why?
|
| Gelsolin | 1 | 2013 | 5 | 0.390 |
Why?
|
| Neural Conduction | 6 | 2020 | 32 | 0.390 |
Why?
|
| Facial Paralysis | 1 | 2013 | 8 | 0.380 |
Why?
|
| Sciatic Neuropathy | 2 | 2011 | 3 | 0.370 |
Why?
|
| Amyloidosis | 1 | 2013 | 70 | 0.360 |
Why?
|
| Dermatomyositis | 1 | 2011 | 11 | 0.350 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 808 | 0.350 |
Why?
|
| Mycophenolic Acid | 1 | 2011 | 68 | 0.340 |
Why?
|
| Meningism | 1 | 2011 | 2 | 0.340 |
Why?
|
| Neck Muscles | 1 | 2011 | 10 | 0.340 |
Why?
|
| Tendinopathy | 1 | 2011 | 11 | 0.340 |
Why?
|
| Reflex, Abnormal | 1 | 2010 | 3 | 0.320 |
Why?
|
| Baroreflex | 1 | 2010 | 22 | 0.320 |
Why?
|
| Meningitis | 1 | 2010 | 18 | 0.320 |
Why?
|
| Radiation Injuries | 1 | 2010 | 67 | 0.310 |
Why?
|
| Autoimmune Diseases | 1 | 2011 | 240 | 0.300 |
Why?
|
| Sensation Disorders | 1 | 2009 | 23 | 0.290 |
Why?
|
| Angina, Unstable | 1 | 2009 | 56 | 0.290 |
Why?
|
| Paclitaxel | 1 | 2009 | 102 | 0.280 |
Why?
|
| Brain Abscess | 1 | 2008 | 7 | 0.280 |
Why?
|
| Meningococcal Infections | 1 | 2008 | 20 | 0.280 |
Why?
|
| Cerebellar Ataxia | 1 | 2008 | 13 | 0.270 |
Why?
|
| Drug-Eluting Stents | 1 | 2009 | 68 | 0.270 |
Why?
|
| Histoplasmosis | 1 | 2008 | 24 | 0.270 |
Why?
|
| Triazoles | 1 | 2008 | 63 | 0.270 |
Why?
|
| Thromboembolism | 1 | 2008 | 74 | 0.270 |
Why?
|
| Pyrimidines | 1 | 2008 | 144 | 0.260 |
Why?
|
| Unnecessary Procedures | 1 | 2006 | 50 | 0.240 |
Why?
|
| Humans | 22 | 2025 | 65826 | 0.230 |
Why?
|
| Polyradiculoneuropathy | 1 | 2005 | 1 | 0.230 |
Why?
|
| Neurosurgical Procedures | 1 | 2006 | 105 | 0.230 |
Why?
|
| Myelin-Associated Glycoprotein | 1 | 2005 | 14 | 0.230 |
Why?
|
| Muscular Dystrophy, Oculopharyngeal | 1 | 2025 | 3 | 0.230 |
Why?
|
| Diagnostic Errors | 1 | 2006 | 106 | 0.230 |
Why?
|
| Myotonic Dystrophy | 1 | 2025 | 14 | 0.220 |
Why?
|
| Myelin Sheath | 1 | 2005 | 39 | 0.220 |
Why?
|
| Male | 15 | 2025 | 31398 | 0.220 |
Why?
|
| Peripheral Nervous System | 1 | 2004 | 13 | 0.220 |
Why?
|
| Water Pollutants, Chemical | 1 | 2025 | 43 | 0.220 |
Why?
|
| Muscular Dystrophy, Facioscapulohumeral | 1 | 2025 | 45 | 0.220 |
Why?
|
| Electromyography | 5 | 2020 | 100 | 0.210 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2004 | 28 | 0.210 |
Why?
|
| Autoantibodies | 1 | 2005 | 186 | 0.210 |
Why?
|
| Middle Aged | 9 | 2025 | 18491 | 0.200 |
Why?
|
| Nervous System Diseases | 1 | 2025 | 109 | 0.200 |
Why?
|
| Adult | 8 | 2025 | 17567 | 0.200 |
Why?
|
| Environmental Exposure | 1 | 2025 | 228 | 0.190 |
Why?
|
| Peripheral Nerves | 2 | 2018 | 34 | 0.190 |
Why?
|
| Diagnosis, Differential | 3 | 2016 | 995 | 0.190 |
Why?
|
| Female | 12 | 2025 | 34414 | 0.180 |
Why?
|
| Treatment Outcome | 4 | 2020 | 5830 | 0.180 |
Why?
|
| Aged | 8 | 2025 | 15141 | 0.170 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2006 | 517 | 0.170 |
Why?
|
| Hand Hygiene | 1 | 2020 | 10 | 0.160 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 26 | 0.160 |
Why?
|
| Antibodies, Neoplasm | 1 | 2020 | 27 | 0.160 |
Why?
|
| Etoposide | 1 | 2020 | 34 | 0.160 |
Why?
|
| Cerebellar Neoplasms | 1 | 2020 | 11 | 0.160 |
Why?
|
| Carcinoma, Small Cell | 1 | 2020 | 23 | 0.150 |
Why?
|
| Carboplatin | 1 | 2020 | 47 | 0.150 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2020 | 59 | 0.150 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 60 | 0.150 |
Why?
|
| Neoplasms | 2 | 2025 | 1377 | 0.150 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 375 | 0.150 |
Why?
|
| Muscle, Skeletal | 2 | 2018 | 789 | 0.140 |
Why?
|
| Rituximab | 2 | 2011 | 89 | 0.140 |
Why?
|
| Biopsy | 2 | 2018 | 463 | 0.140 |
Why?
|
| Prednisone | 1 | 2018 | 83 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 206 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 220 | 0.130 |
Why?
|
| Leg | 2 | 2008 | 87 | 0.120 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 169 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 466 | 0.120 |
Why?
|
| Disease Progression | 1 | 2020 | 1229 | 0.110 |
Why?
|
| Anxiety | 1 | 2018 | 427 | 0.110 |
Why?
|
| Lambert-Eaton Myasthenic Syndrome | 1 | 2013 | 1 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 712 | 0.090 |
Why?
|
| Diabetes Complications | 1 | 2013 | 106 | 0.090 |
Why?
|
| Phenotype | 1 | 2016 | 1236 | 0.090 |
Why?
|
| Hashimoto Disease | 1 | 2011 | 3 | 0.090 |
Why?
|
| Dermatologic Agents | 1 | 2011 | 24 | 0.090 |
Why?
|
| Neuroimaging | 1 | 2013 | 170 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 463 | 0.080 |
Why?
|
| Muscular Diseases | 1 | 2010 | 51 | 0.080 |
Why?
|
| Paresthesia | 1 | 2009 | 7 | 0.070 |
Why?
|
| Coronary Restenosis | 1 | 2009 | 21 | 0.070 |
Why?
|
| Antirheumatic Agents | 1 | 2011 | 227 | 0.070 |
Why?
|
| Sjogren's Syndrome | 1 | 2009 | 25 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 1 | 2010 | 166 | 0.070 |
Why?
|
| Angioplasty, Balloon | 1 | 2009 | 56 | 0.070 |
Why?
|
| Immune System | 1 | 2010 | 133 | 0.070 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2008 | 1 | 0.070 |
Why?
|
| Disease Susceptibility | 1 | 2009 | 170 | 0.070 |
Why?
|
| Umbilical Arteries | 1 | 2008 | 10 | 0.070 |
Why?
|
| Voriconazole | 1 | 2008 | 5 | 0.070 |
Why?
|
| Liver Abscess | 1 | 2008 | 18 | 0.070 |
Why?
|
| Itraconazole | 1 | 2008 | 14 | 0.070 |
Why?
|
| Bone Marrow Diseases | 1 | 2008 | 14 | 0.070 |
Why?
|
| Arm | 1 | 2008 | 45 | 0.070 |
Why?
|
| Arteriovenous Malformations | 1 | 2008 | 45 | 0.070 |
Why?
|
| Pediatrics | 1 | 2011 | 265 | 0.070 |
Why?
|
| Frontal Lobe | 1 | 2008 | 63 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 214 | 0.070 |
Why?
|
| Catheterization | 1 | 2008 | 112 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2010 | 264 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2025 | 2737 | 0.070 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2011 | 347 | 0.070 |
Why?
|
| Blood Pressure | 1 | 2010 | 537 | 0.070 |
Why?
|
| Cerebellum | 1 | 2008 | 94 | 0.070 |
Why?
|
| Bacteremia | 1 | 2008 | 91 | 0.060 |
Why?
|
| Antifungal Agents | 1 | 2008 | 125 | 0.060 |
Why?
|
| Recurrence | 1 | 2009 | 665 | 0.060 |
Why?
|
| Arthropathy, Neurogenic | 1 | 2006 | 5 | 0.060 |
Why?
|
| Radiculopathy | 1 | 2006 | 21 | 0.060 |
Why?
|
| Early Diagnosis | 1 | 2006 | 95 | 0.060 |
Why?
|
| Spinal Cord Diseases | 1 | 2006 | 44 | 0.060 |
Why?
|
| Child | 3 | 2013 | 4653 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2025 | 6953 | 0.060 |
Why?
|
| Hypesthesia | 1 | 2005 | 8 | 0.060 |
Why?
|
| Gait Ataxia | 1 | 2005 | 3 | 0.060 |
Why?
|
| Siblings | 1 | 2005 | 41 | 0.060 |
Why?
|
| Mobility Limitation | 1 | 2025 | 49 | 0.050 |
Why?
|
| Leprostatic Agents | 1 | 2004 | 3 | 0.050 |
Why?
|
| Embolization, Therapeutic | 1 | 2008 | 338 | 0.050 |
Why?
|
| Mutation | 1 | 2013 | 2674 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2005 | 108 | 0.050 |
Why?
|
| Age Factors | 1 | 2008 | 1595 | 0.050 |
Why?
|
| Disability Evaluation | 1 | 2005 | 216 | 0.050 |
Why?
|
| Recovery of Function | 1 | 2005 | 293 | 0.050 |
Why?
|
| Nerve Fibers | 1 | 2003 | 32 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 1665 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2008 | 2088 | 0.050 |
Why?
|
| Muscles | 1 | 2003 | 179 | 0.050 |
Why?
|
| Young Adult | 2 | 2025 | 4878 | 0.040 |
Why?
|
| Motor Neurons | 1 | 2003 | 219 | 0.040 |
Why?
|
| Adolescent | 2 | 2011 | 6367 | 0.040 |
Why?
|
| Prevalence | 1 | 2025 | 1453 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2005 | 875 | 0.040 |
Why?
|
| Decontamination | 1 | 2020 | 12 | 0.040 |
Why?
|
| Masks | 1 | 2020 | 20 | 0.040 |
Why?
|
| Equipment Contamination | 1 | 2020 | 34 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2010 | 5681 | 0.040 |
Why?
|
| United States | 2 | 2025 | 8190 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 106 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 182 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2020 | 318 | 0.030 |
Why?
|
| HIV Infections | 1 | 2004 | 961 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2018 | 382 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 692 | 0.030 |
Why?
|
| Mass Screening | 1 | 2020 | 700 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1291 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2018 | 3339 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 2790 | 0.020 |
Why?
|
| Creatine Kinase | 1 | 2010 | 42 | 0.020 |
Why?
|
| Withholding Treatment | 1 | 2010 | 38 | 0.020 |
Why?
|
| Muscle Weakness | 1 | 2010 | 33 | 0.020 |
Why?
|
| Necrosis | 1 | 2010 | 148 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 2496 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 382 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2010 | 274 | 0.020 |
Why?
|
| Animals | 1 | 2004 | 21489 | 0.010 |
Why?
|
| Infant | 1 | 2011 | 1720 | 0.010 |
Why?
|